ProCR™

Modified Release: ProCR™ Technology

ProCR™ is a matrix tablet formulated with a combination
of three commercially available polymers.

• Novel composition
• Three commercially available polymers
• Near linear release
• Applicable to a wide range of doses and drug solubility
• Patents filed in 4Q08
• Flexible array of drug release profiles

Delayed-Extended Release

• Coating applied to ProCR™ tablets can provide a delayed-extended release.
• Customized profile achieved by changing coating porosity or thickness.

ProCR™ Dissolution Profiles of Three Drug Candidates

Potential Benefits:

• Improved Therapy
• Decrease number of daily doses improves compliance
• Decrease adverse effects due to better plasma concentration control
• Customizable Release Profile: Burst, Extended, Delayed

ProCR™: Case Study Comparison to Procardia XL®

• Procardia XL® (nifedipine) is very insoluble
• Only match is an osmotic tablet (more expensive to manufacture)
• Two AAIPharma formulations match innovator profile in-vitro
• Osmotic performance without manufacturing complexity
• PK study scheduled for August 2009 to confirm in-vivo correlation